Additional file 1 of Establishment of tumor microenvironment-preserving organoid model from patients with intracranial meningioma
Creators: name: Kim, Dokyeong
name: Park, Junseong
name: Park, Hyeon-Chun
name: Zhang, Songzi
name: Park, Minyoung
name: Park, Soon A.
name: Lee, Sug Hyung
name: Lee, Youn Soo
name: Park, Jae-Sung
name: Jeun, Sin-Soo
name: Chung, Yeun-Jun
name: Ahn, Stephen
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Cell Biology
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Neuroscience
subject: Pharmacology
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Biological Sciences not elsewhere classified
subject: Information Systems not elsewhere classified
subject: Cancer

description: Additional file 1. Fig. S1: Masson’s trichrome staining in MNOs and their parental tumors. Collagen-rich tissue (blue) was observed using Masson’s trichrome in MNOs (top) and their corresponding tumors (bottom). Blue = collagen fiber; red/pink = cytoplasm; dark red/purple = nuclei. Scale bars: upper images = 200 μm; lower images = 20 μm. Glioblastoma organoid (GBO) was used as a negative control. Fig. S2: IF images of marker proteins in MNOs. IF images using antibodies against EMA, Vimentin, CD31, ICAM1, CD68, and Iba1 in all MNOs. Lower panels show the enlarged areas marked by boxes in the upper panels. The nuclei were counterstained with Hoechst. White scale bars = 100 μm; yellow scale bars = 20 μm. Fig. S3: DAB staining images for CD68 and ICAM1 in MNOs and their parental tumors. A, B DAB staining for CD68 (A) and ICAM1 (B) in MNOs (lower panel) and parental meningioma tissues (upper panel). Scale bars indicate 200 μm (top) and 20 μm (bottom, enlarged images). C Quantification of the expression levels of CD68 (left) and ICAM1 (right). Two-tailed Student’s t-test was conducted to evaluate statistical significance. Fig. S4: WES of MNOs and corresponding parental tumors. A, B The number of variants and their types for each sample. C The number of each class of single nucleotide variants. D, E Venn diagram of the number of short variants (single nucleotide variants, insertions, and deletions) for parental tumors (D) and MNOs (E). Fig. S5: H&amp;E and IHC images after treatment with mifepristone in MNO21-02. H&amp;E and immunostaining (PR, EMA, Vimentin, CD68, and CD31) images were captured after treatment with mifepristone for 72 h. Lower panels show the enlarged areas marked by boxes in the upper panels. The nuclei were counterstained with Hoechst in IF images. Scale bars indicate 200 μm (top) and 20 μm (bottom) in H&amp;E and DAB staining images, and indicate 100 μm (top and bottom) in IF images. Fig. S6: H&amp;E and IHC images after treatment with mifepristone in MNO21-01. H&amp;E and immunostaining (PR, EMA, Vimentin, CD68, and CD31) images were captured after treatment with mifepristone for 72 h. Lower panels show the enlarged areas marked by boxes in the upper panels. The nuclei were counterstained with Hoechst in IF images. Scale bars indicate 200 μm (top) and 20 μm (bottom) in H&amp;E and DAB staining images, and indicate 100 μm (top and bottom) in IF images. Fig. S7: H&amp;E and IHC images after treatment with mifepristone in MNO22-01. H&amp;E and immunostaining (PR, EMA, Vimentin, CD68, and CD31) images were captured after treatment with mifepristone for 72 h. Lower panels show the enlarged areas marked by boxes in the upper panels. The nuclei were counterstained with Hoechst in IF images. Scale bars indicate 200 μm (top) and 20 μm (bottom) in H&amp;E and DAB staining images, and indicate 100 μm (top and bottom) in IF images. Table S1: The information of antibodies used for immunostaining.